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Strength and limitations of this study
 ► The benefits of exercise physiology services for type 
2 diabetes (BEST) study intervention is the delivery
of routine, real-world Exercise Physiology services
to manage type 2 diabetes as opposed to a clinical
exercise trial.
 ► The study employs multiple sites across Australia to
reach recruitment targets.
 ► There is a risk of losing participants during the
6-month intervention as Exercise Physiology ser-
vices may be delivered for a duration shorter than
the intervention.
 ► The study is a non-randomised trial due to the re-
al-world nature of the study.
AbStrACt
Introduction Controlled trials support the efficacy of 
exercise as a treatment modality for chronic conditions, yet 
effectiveness of real-world Exercise Physiology services 
is yet to be determined. This study will investigate the 
efficacy and cost-effectiveness of services provided by 
Accredited Exercise Physiologists (AEPs) for clients with 
type 2 diabetes (T2D) in clinical practice.
Methods and analysis A non-randomised, opportunistic 
control, longitudinal design trial will be conducted at ten 
Exercise Physiology Clinics. Participants will be individuals 
with T2D attending one of the Exercise Physiology 
Clinics for routine AEP services (exercise prescription 
and counselling) (intervention) or individuals with T2D 
not receiving AEP services (usual care) (control). The 
experimental period will be 6 months with measurements 
performed at baseline and at 6 months. Primary outcome 
measures will be glycosylated haemoglobin (HbA1c), 
resting brachial blood pressure (BP), body mass index, 
waist circumference, 6 min walk test, grip strength, 
30 s sit to stand, Medical Outcomes Short-Form 36-
Item Health Survey and Active Australia Questionnaire. 
Secondary outcomes will be medication usage, out-of-
pocket expenses, incidental, billable and non-billable 
health professional encounters and work missed through 
ill health. Healthcare utilisation will be measured for 
12 months prior to, during and 12 months after trial 
participation using linked data from Medicare Benefits 
Schedule and Pharmaceutical Benefits Scheme data.
Ethics and dissemination The study is a multicentre 
trial comprising: University of Tasmania, University of New 
South Wales Lifestyle Clinic, University of Canberra, Baker 
Heart and Diabetes Institute (covered under the ethics 
approval of University of Tasmania Health and Medical 
Ethics Committee H0015266), Deakin University (Approval 
number: 2016–187), Australian Catholic University 
(2016–304R), Queensland University of Technology 
(1600000049), University of South Australia (0000035306), 
University of Western Australia (RA/4/1/8282) and 
Canberra Hospital (ETH.8.17.170). The findings of this 
clinical trial will be communicated via peer-reviewed 
journal articles, conference presentations, social media 
and broadcast media.
trial registration number ACTRN12616000264482.
IntroduCtIon
Diabetes is estimated to affect over 422 million 
individuals globally,1 with type 2 diabetes 
(T2D) accounting for approximately 90% of 
diabetes incidence.2 Rising levels of physical 
inactivity and obesity are important contribu-
tors to the alarming increase in the incidence 
of T2D.3 In Australia, over 29% of adults are 
insufficiently active and 14% inactive (Austra-
lian Health Survey 2011–2012). In combina-
tion with its contribution to chronic disease 
burden, T2D is associated with a significant 
economic burden4 with a total annual cost in 
Australia of up to $6 billion.5 With a twofold 
increase in the prevalence of diabetes in 
recent years,6 and no known cure, preven-
tion and management strategies are key to 
successfully address this major public health 
burden.
There is substantial evidence from 
randomised controlled trials regarding the 
benefits of exercise training in diabetes 
management.7–9 Structured exercise training 
involving aerobic exercise, resistance exercises 
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or a combination of both is associated with improvements 
in glycaemic control,10 muscle microvascular blood flow,11 
muscle strength12 and quality of life.13 14 While controlled 
clinical studies, often conducted in hospital and univer-
sity laboratory settings, demonstrate the effectiveness of 
exercise in the management of T2D, studies that have 
assessed the feasibility and outcomes of evidence-based 
exercise prescription in a real-world practice setting are 
scarce. Importantly, health benefits shown in clinical 
trials have not yet been proven to translate into practice 
where the adoption of and adherence to exercise is often 
more challenging.15
Primary healthcare is the main setting for T2D diag-
nosis, treatment and referral pathways,16 and people with 
T2D tend to have long-term patient:client relationships 
with their general practitioners17 and consider them as 
credible sources of health-related information. This 
regular and positively viewed interaction provides an 
opportune environment for the promotion of lifestyle 
medicine, and initiatives such as“‘Exercise is Medicine’ 
have been introduced to implement strategies in order 
to promote the effectiveness of physical activity in the 
healthcare setting.18 A recent meta-analysis19 reports 
that exercise referral in a primary healthcare setting was 
associated with a small increase in the adoption of phys-
ical activity (relative risk 1.12; 95% CI 1.04 to 1.20). In 
contrast, a systematic review by Pavey et al20 reports limited 
evidence on the clinical and cost-effectiveness of exercise 
referral in comparison with usual care. In the majority of 
the studies included in these systematic reviews, patients 
were referred to a non-descript exercise professional and 
a short-term (10–12 weeks) leisure centre-based interven-
tion. The effectiveness of exercise referral to an exercise 
specialist for specific disease management is yet to be 
determined.
Accredited Exercise Physiologists (AEPs) are allied 
health professionals who have been trained to prescribe 
exercise and facilitate long-term behavioural change 
through exercise counselling in subclinical and clinical 
populations. While exercise prescription is the main 
treatment modality used by AEPs, counselling skills are 
also employed to facilitate behavioural change. AEPs 
have the professional competencies to assess clients and 
design and implement effective, individualised exercise 
interventions for people with T2D who often have signif-
icant comorbidities. Lifestyle intervention programmes 
are effective in reducing the progression of chronic 
disease21 22; however, the effects persist only as long as the 
new lifestyle is maintained.23
Interventions led by AEPs have been effective in 
increasing physical activity levels in insufficiently active 
adults.24 However, the only previous study that to our 
knowledge has examined an AEP-led exercise interven-
tion in chronic disease evaluated the health economics 
associated with the intervention rather than efficacy 
in improving exercise/physical activity behaviour, clin-
ical status, function and quality of life.25 The aim of this 
study is therefore to: (1) investigate the effectiveness of 
real-world Clinic AEP services for individuals with T2D 
on (A) sustained participation in physical activity and 
(B) surrogate markers of clinical prognosis including
cardiovascular and metabolic risk; (2) estimate the associ-
ation between different levels of session participation and
surrogate markers of clinical prognosis; and (3) estimate
the relative cost-effectiveness of different frequencies of
attendance.
MEthodology
trial design and setting
This study comprises a non-randomised, opportunistic 
control, longitudinal design examining the effects of 
different levels of participation of individuals with T2D 
with Exercise Physiology services on surrogate measures 
of diabetes progression in real-world settings. Any amend-
ments (if required) will be ethically approved through 
each site’s ethics committee and communicated by the 
trial manager to relevant parties.
Participants
Intervention group participants will be adults (>18 years) 
recruited from clients referred to participating clinics 
for Exercise Physiology services. All consecutive patients 
attending one of the trial centres meeting the inclusion 
criteria of having T2D and receiving AEP services are 
eligible for the intervention group. Exclusion criteria 
are clinically unstable patients (defined as medical 
factors that make exercise unsafe or patients with undiag-
nosed signs or symptoms suggestive of unstable chronic 
disease),26 with contraindications to exercise or already 
engaged in high levels of physical activity. Participants will 
undergo standard AEP services, which will include: an 
assessment of variables associated with physical function 
and clinical status on their initial visit to an AEP, subse-
quent individualised supervised and unsupervised exer-
cise sessions based on published exercise guidelines for 
individuals with T2D27 with the dose and exact content 
determined by the supervising AEP in negotiation with 
each participant’s preferences and clinical status, coun-
selling on exercise adherence and a follow-up assess-
ment after approximately 6 months. A control group will 
include participants who are not referred to Exercise 
Physiology services or who are on an extended waiting 
list for Exercise Physiology treatment and are willing to 
undergo an assessment of physical function and clinical 
status at baseline and following 6 months. This group will 
be recruited from clients referred for other treatments 
at participating clinics and from university staff and 
students of participating university clinics who have previ-
ously been diagnosed with T2D but have not received 
any AEP services. These individuals will be recruited via 
local flyers and social media. Participants will provide 
informed consent obtained from the treating AEP or trial 
coordinator. To avoid loss to follow-up, patients will be 
contacted during the follow-up period to remind them 
of any scheduled visits. To date, 126 of the anticipated 
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Figure 1 Flow chart of the study process. AEP, Accredited 
Exercise Physiologist; MBS, Medical Benefits Schedule; PBS, 
Pharmaceutical Benefits Scheme.
555 participants have been recruited (124 treatment and 
2 controls). A flow chart of the study process is shown in 
figure 1. This trial protocol was developed according to 
the Standardized Protocol Items: Recommendations for 
Interventional Trials guidelines (see online supplemen-
tary file 1).
data collection
Data will be collected from all clients with T2D attending 
any of the participating Exercise Physiology Clinics in 
the trial period (April 2016–January 2021) who have 
provided written informed consent. Outcome data 
pertaining to quality of life and markers of clinical prog-
nosis and cardiovascular risk will be collected at baseline 
and after 6 months. The number of sessions with an Exer-
cise Physiologist, whether or not clients received treat-
ment from other allied health professionals (ie, dietitian) 
and compliance with counselling (measured by physical 
function and participation in physical activity) will be 
recorded and used as predictor covariates in the statis-
tical analyses. Data will be collected at each study site in 
custom-written Access databases (Microsoft Office 2010, 
Microsoft Corporation, Washington, USA). Each local 
database is uniquely coded for the study site. Deidenti-
fied data will be exported from the local databases and 
imported into a master chart for reporting and analysis. 
Trial data will be audited on a regular basis by the trial 
manager. Primary outcome measures will be glycosylated 
haemoglobin (HbA1c), resting brachial blood pressure 
(BP), body mass index (BMI), waist circumference, 
6 min walk test, grip strength, 30 s sit to stand, Medical 
Outcomes Short-Form 36-Item Health Survey and Active 
Australia Questionnaire. Secondary outcomes will be 
medication usage, out-of-pocket expenses, incidental, 
billable and non-billable health professional encounters 
and work missed through ill health. Outcome data for the 
intervention group will be analysed against baseline data 
using mixed methods regression corrected for repeated 
measures with potential contributing variables such as 
age, gender, comorbidities, medications, self-reported 
participation, number of client AEP consultations, other 
allied health interventions and type of exercise prescrip-
tion (eg, supervised or unsupervised and at home or in 
a community setting) included in the analysis as covari-
ates. Healthcare resource utilisation will be measured for 
12 months prior to enrolment, during the intervention 
and 12 months after trial participation for both interven-
tion and control groups using linked data from Medicare 
Benefits Schedule (MBS) and Pharmaceutical Benefits 
Scheme (PBS) data. Medication usage, out-of-pocket 
expenses, incidental, billable and non-billable health 
professional encounters and work missed through ill 
health will be assessed by health diaries. The timing of 
study measurements is provided in table 1.
Anthropometry
Height will be measured to the nearest 0.1 cm using a 
wall-mounted stadiometer and body weight to the nearest 
0.1 kg using digital scales. BMI will be calculated. Waist 
circumference will be measured using the cross hand 
technique (left hand under) at the narrowest point, or at 
the midpoint between lowest rib and top of iliac crest if 
the narrowest point is not apparent. These measures are 
simple and easy to obtain and have been widely used as 
indicators of cardiovascular disease risk28 and mortality29 
risk in large-scale population studies.
Physical function
The 6 min walk test (6MWT) will be used as a measure 
of physical function as the cardiovascular mortality risk 
is increased with walking distance of less than 350 m.30 
Briefly, participants will be instructed to walk as far as 
possible along a short measured course during the 6 min. 
They will be permitted to stop and rest if needed and will 
receive standardised verbal feedback if the client stops 
walking or needs a rest during the test and 15 s prior to test 
completion. The 6MWT is a reliable and valid measure of 
physical function in older adults.31
Musclar strength and endurance
Strength will be measured using grip strength and 
muscular endurance with the 30s sit to stand (30 s STS). 
Grip strength is a reliable and valid measure of upper body 
strength32 and has been linked to outcomes, including 
mortality, in chronic disease.33 Grip strength will be 
measured with participants leaning forward slightly, 
with the hand to be tested in front, not touching the 
body; forearm will be slightly bent in a neutral position, 
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Table 1 Overview of study measurements and time points for data collection
Time point
Screening Intervention period Follow-up
Initial visit Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7
Eligibility x
Informed consent x
Allocation x
Intervention:
AEP services x x x x x x
Usual care x x x x x x
Baseline 
measures
6-month
follow-up
Participant demographics x x
Medical history x x
HbA1c x x
Blood pressure x x
BMI x x
Waist circumference x x
6 min walk test x x
Grip strength x x
30 s sit to stand x x
SF-36 x x
Active Australia 
Questionnaire
x x
Self-reported medication 
usage
x x x x x x x x
Self-reported access 
of health professional 
services
x x x x x x x x
Self-reported out-of-pocket 
health expenses
x x x x x x x x
Self-reported work missed 
through ill health
x x x x x x x x
MBS data 12 months 
prior
x x x x x x 12 months 
following 
intervention/
control 
period
PBS data 12 months 
prior
x x x x x x 12 months 
following 
intervention/
control 
period
AEP, Accredited Exercise Physiologist; BMI, body mass index; HbA1c, glycosylated haemoglobin; MBS, Medicare Benefits Schedule; PBS, 
Pharmaceutical Benefits Scheme.
avoiding pronation or supination of the wrist as this has 
been shown to alter the measurement. Participants will be 
instructed to perform a maximum gripping effort for a 
few seconds while keeping the arm stationary. Two to four 
trials will be conducted on each arm with trials ceased 
on no further improvement, and the maximum scores for 
the right and left hands will be added together.
30 s STS is a measure of lower extremity muscular 
endurance and function and relates to ability to perform 
activities of daily living. It is a reliable and valid measure 
that is widely used in clinical practice.34 The participant 
will be seated in a chair then instructed to fold their arms 
across their chest and to stand fully upright and sit down 
as many times as possible in 30 s.
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Self-perceived physical function and health-related quality of 
life
Self-perceived physical function and health-related quality 
of life will be evaluated using the Medical Outcomes 
Short-Form 36-Item Health Survey (SF-36). This survey 
includes eight independent scales (physical functioning, 
role physical, bodily pain, general health, vitality, social 
functioning, role emotional and mental health) that are 
collapsed to create two global components of physical 
and mental dimensions of health. It is validated and has 
been widely used to measure quality of life in a range of 
chronic disease populations.35–37 The client is provided 
with a copy of the SF-36 and asked to answer all 36 ques-
tions as honestly as possible. The SF-36 will be divided 
into two summary measures: the Physical Component 
Summary and the Mental Component Summary.
Self-reported physical activity
Physical activity will be measured using the Active 
Australia questionnaire.38 Participants will be requested 
to include any exercise performed in the previous 
week in their response to the questionnaire. The survey 
measures frequency, intensity and duration of incidental 
and/or intentional physical activity in the week prior to 
the time of testing. The total time spent in each activity 
will be multiplied by an intensity value (corresponding 
Metabolic Equivalent; MET) and used to calculate partic-
ipants’ weekly physical activity in MET/min. This survey 
is valid and reliable39 40 and has previously been used to 
measure changes in physical activity in chronic disease 
populations.36
glycosylated haemoglobin
Glycosylated haemoglobin (HbA1c) is a measurement 
of long-term glucose load in the bloodstream. Elevated 
concentrations of glucose in the blood react with haemo-
globin in the bloodstream resulting in the haemoglobin 
becoming glycosylated. The concentration of HbA1c in 
the blood gives an indication of the glucose load over 
a prolonged time period (~3 months). As a result, this 
method is considered a better indicator of glucose intol-
erance and severity of metabolic disease than random 
blood glucose levels that are highly dependent on factors 
such as the length of time since the last meal. HbA1c is 
measured on a quarterly basis as part of routine diabetes 
management by a general practitioner. The most recent 
pathology results will be used to indicate HbA1c on 
commencement of the Exercise Physiology treatment 
and following 6 months.
blood pressure
Blood pressure will be measured by sphygmomanometry 
using standardised techniques after 5 min of seated rest. 
To prevent short-term blood pressure increases, partici-
pants will be advised not to consume caffeine, exercise or 
smoke, 2 hours prior to assessment in line with recently 
published guidelines.41
health costs information
Healthcare resource utilisation in the form of medical 
services received and prescribed medications received 
will be determined for 12 months prior to enrolment, 
during the intervention and 12 months after trial partic-
ipation for both intervention and control groups using 
linked data from the MBS and PBS data. Medication 
usage, out-of-pocket expenses, incidental, billable and 
non-billable health professional encounters and work 
missed through ill health will be assessed by health diaries. 
Participants will be asked to record information in the 
diary on days when health services are required or when 
poor health prevents them from completing their usual 
activities. Participants will be provided with the diary and 
examples of how to complete the required information. 
Participants will detail information relating to the nature 
of their illness, any appointments with medical or allied 
health practitioners, appointment length and a brief 
description of what the appointment involved. Details 
about out-of-pocket costs (total fees charged by a medical 
specialist minus any Medicare rebates) associated with 
the illness/appointment will also be recorded (this may 
include the cost of the appointment itself, medications or 
equipment).
Cost-effectiveness analysis
Incremental cost-effectiveness ratios will be calculated as 
the difference in direct and indirect costs between the two 
groups, divided by the incremental quality-adjusted life 
years gained (derived from SF-36-derived health utilities).
reproducibility of study procedures
A manual of standard operations and procedures has 
been developed to standardise all testing procedures and 
Exercise Physiologist training in areas including patient 
recruitment, measurement, assessment, data entry, secu-
rity and management to assist reliability and accuracy of 
measures obtained across all participating sites.
data analysis
Sample size was calculated on the basis of participant 
numbers required to achieve statistically and clinically 
significant differences in HbA1c (alpha=0.05) on both 
between group (intervention vs control) and within group 
(intervention participants divided into two groups on the 
basis of exercise compliance) analyses.42 The calculation 
revealed that 99 participants will be required per group 
to detect a change in HbA1c of 0.4%, SD 1.0, power 80%. 
As potential difficulties are expected in accessing patients 
with T2D who have not received a referral for Exercise 
Physiology services, as well as budgetary constraints, we 
have performed a sample size calculation for unequal 
groups (http:// epitools. ausvet. com. au/ content. php? 
page= 2Means2). This calculation indicated that we 
require 500 individuals in the intervention group and 
55 individuals in the control group. Consequently, 500 
individuals with T2D who have been referred for an 
Exercise Physiology intervention will be recruited for 
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the intervention, while 55 patients with T2D who are not 
receiving Exercise Physiology services will be recruited for 
the control group by opportunistic sample.
Intervention versus control group data will be assessed 
for changes in health-related variables and behaviours 
over time via mixed methods linear regression. Where 
assumptions of linear regression are violated, data will be 
analysed using non-parametric analysis via ordinal logistic 
regression. Outcome data for the intervention group will 
be analysed against baseline data using adjusted and 
unadjusted mixed methods regression with potential 
contributing variables such as age, gender, comorbidities, 
medications, self-reported participation, number of client 
Exercise Physiology consultations, other allied health 
interventions and types of exercise prescription (home 
based or community setting) considered in the modelling 
as potential covariates. The internal cost-effectiveness of 
the programme (the relationship between rising exer-
cise clinic costs as treatment frequency increases against 
improving exercise compliance with counselling) will also 
be estimated. Analyses will be performed using STATA SE 
15.0 with statistical significance set at p<0.05.
Patient and public involvement
Patients or the public were not directly involved in the 
design of this study. The study is designed to quantify 
the effectiveness of Exercise Physiology services that are 
routinely delivered in a best-practice, patient-centred 
manner.
dISCuSSIon
Effective management strategies are required to address 
the increasing global epidemic of T2D. Controlled trials 
support the efficacy of exercise as a treatment modality,7–9 
and clinical trials have demonstrated the effectiveness of 
Exercise Physiologists to influence long-term behavioural 
change in insufficiently active adults.24 Additionally, a 
commissioned report in 2015 on the value of Accredited 
Exercise Physiologists in Australia suggested health system 
cost savings of up to $5107 per person (cost benefit ratio 
of 8.8 to 1) for individuals with T2D accessing Exercise 
Physiology services,43 under the assumption that efficacy 
from clinical trials translated to real-world Exercise Phys-
iology services. On the basis of assumptions that Exercise 
Physiology services are effective, an individual with T2D in 
Australia may access up to eight group and five individual 
Exercise Physiology services in a calendar year following 
an appropriate referral from their general practitioner. 
Despite this, the effectiveness of real-world Exercise Phys-
iology services in Australia is yet to be determined.
This study is unique as it aims to bridge an important 
gap between controlled, clinical trials and real-world 
practice, where the effectiveness of the translation of this 
evidence base to health improvements requires quantifi-
cation. The work will quantify the health and economic 
outcomes of Exercise Physiology services for T2D in a 
real-world setting, providing valuable data for facilitating 
the management strategies of T2D and also may help in 
developing health policies for T2D patients.
EthICS And dISSEMInAtIon
The study will be conducted in accordance with the 
National Health and Medical Research Council national 
statement on ethical conduct in research, as well as the 
approved study protocol. A detailed participant infor-
mation sheet will be provided to each individual prior to 
them providing written, informed consent.
The findings of this clinical trial will be communi-
cated using a comprehensive dissemination strategy 
that includes peer-reviewed journal articles, confer-
ence presentations, social media and broadcast media. 
No professional writers are intended to be used in the 
preparation of associated presentations, manuscripts and 
materials, and author eligibility will be determined using 
the International Committee of Medical Journal Editors 
authorship guide.
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